Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
Minneapolis, Minn. & Irvine, Calif., October 3, 2018 – Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks.
By pairing Cryoport’s expertise in temperature controlled logistics with Be The Match BioTherapies’ expertise in apheresis center onboarding and management, case management and logistics, clinical research, and outcomes data collection and analysis, the two organizations will offer full end-to-end supply chain and outcomes support for companies developing and delivering autologous and allogeneic cell and gene therapies. An important part of the agreement is to integrate Be The Match BioTherapies’ MatchSource® cell therapy supply chain software and Cryoport’s Cryoportal™ Logistics Management Platform. The outcome is a platform that manages more cell therapy products than any other solution in the marketplace, enabling cell and gene therapy companies to more rapidly discover, develop and deliver next-generation therapies.
Cryoport recently launched Chain of ComplianceTM, a solution that offers full traceability and provides comprehensive data that, when combined with Be The Match BioTherapies’ assets, including MatchSource, manages risk and provides the industry with a cell therapy standardization platform. With services powered by the National Marrow Donor Program®/Be The Match® and more than 30 years of experience, Be The Match BioTherapies’ expertise includes the management of 22,000 cell and blood shipments annually and a successful compliance record in managing chain of identity.
“We are delighted to partner with Cryoport to support the growing cell and gene therapy industry,” said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies. “This new partnership will leverage the strengths of Cryoport and Be The Match BioTherapies to provide a unique set of standardized end-to-end workflow and logistics management services—beginning with cell harvest at apheresis centers, continuing through the supply chain, and ending with outcomes tracking—for the cell and gene therapy industry.”
“Be The Match BioTherapies is leading the charge to develop a more efficient and standardized cell therapy supply chain. We are pleased to join them in these industry-leading efforts and look forward to working together to support cell and gene therapy companies to more efficiently bring new medicines to patients,” said Mark Sawicki, chief commercial officer of Cryoport.
About Be The Match BioTherapies
Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program/Be The Match, and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance cell and gene therapies in any stage of development.
Be The Match BioTherapies is dedicated to providing high-quality cellular starting material consented for research, clinical and commercial use, developing and managing expansive cell collection networks, and navigating cell therapy regulatory compliance. Using proven infrastructure to successfully manage autologous and allogeneic cell therapy supply chains, including MatchSource Supply Chain Software, personalized case managers and logistics experts, the organization has a history of compliance managing the chain of identity. The collaboration with CIBMTR extends services to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.
About Cryoport, Inc.
Cryoport is a trusted global provider of solutions for maintaining temperature-sensitive life sciences commodities during distribution, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, and technical development risks. The Company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the Company’s 10-K for the year ended December 31, 2017 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.